Current perspectives of cardio‐oncology: Epidemiology, adverse effects, pre‐treatment screening and prevention strategies
Open Access
- 27 April 2023
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 12 (13) , 14545-14555
Abstract
Cancer and cardiac diseases are the most prevalent causes of death in most developed countries. Due to the earlier detection and higher effectiveness of treatment, more patients survive the disease and have a long life expectancy. As the post‐cancer population is growing, an increasing number of patients will be diagnosed with sequelae of those therapies, most often affecting the cardiovascular system. Although the risk of cancer recurrence decreases within years, the risk of cardiac complications—for example left ventricle (LV) systolic and diastolic dysfunction, arterial hypertension, arrhythmias, pericardial effusion and premature coronary artery disease remains elevated for decades after the completion of the therapy. The most common anticancer therapies that can cause adverse cardiovascular effects include chemotherapy—in particular anthracyclines, human epidermal growth receptor 2 targeted drugs and radiation therapy. A new field of research, cardio‐oncology, addresses this increasing risk, screening, diagnosis and prevention. This review aims to present the most relevant reports regarding the adverse cardiac effects of oncological therapy, including the most prevalent types of cardiotoxicity, methods of pre‐treatment screening and indications for prevention therapy.Keywords
This publication has 60 references indexed in Scilit:
- Normal Ranges of Left Ventricular Strain: A Meta-AnalysisJournal of the American Society of Echocardiography, 2013
- Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline ChemotherapyJACC, 2012
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Impact of Progression of Diastolic Dysfunction on Mortality in Patients With Normal Ejection FractionCirculation, 2012
- Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative StressHypertension, 2012
- Prediction of All-Cause Mortality From Global Longitudinal Speckle StrainCirculation: Cardiovascular Imaging, 2009
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malateAnnals of Oncology, 2008
- Endothelin-1 Vasoconstrictor Tone Increases With Age in Healthy Men But Can Be Reduced by Regular Aerobic ExerciseHypertension, 2007
- Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytesExperimental Cell Research, 2007
- Congestive heart failure in patients treated with doxorubicinCancer, 2003